These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9184116)

  • 21. The therapeutic effects of dopamine replacement therapy and its psychiatric side effects are mediated by pineal function.
    Willis GL
    Behav Brain Res; 2005 May; 160(1):148-60. PubMed ID: 15836910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pleiotrophin receptor RPTP-zeta/beta expression is up-regulated by L-DOPA in striatal medium spiny neurons of parkinsonian rats.
    Ferrario JE; Rojas-Mayorquín AE; Saldaña-Ortega M; Salum C; Gomes MZ; Hunot S; Raisman-Vozari R
    J Neurochem; 2008 Oct; 107(2):443-52. PubMed ID: 18752647
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.
    Di Stefano A; Carafa M; Sozio P; Pinnen F; Braghiroli D; Orlando G; Cannazza G; Ricciutelli M; Marianecci C; Santucci E
    J Control Release; 2004 Sep; 99(2):293-300. PubMed ID: 15380638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
    Lee WY; Lee EA; Jeon MY; Kang HY; Park YG
    Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase.
    Leff SE; Rendahl KG; Spratt SK; Kang UJ; Mandel RJ
    Exp Neurol; 1998 Jun; 151(2):249-64. PubMed ID: 9628761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L-DOPA and psychosis: evidence for L-DOPA-induced increases in prefrontal cortex dopamine and in serum corticosterone.
    Carey RJ; Pinheiro-Carrera M; Dai H; Tomaz C; Huston JP
    Biol Psychiatry; 1995 Nov; 38(10):669-76. PubMed ID: 8555378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.
    Muriel MP; Orieux G; Hirsch EC
    Mov Disord; 2002 Nov; 17(6):1174-9. PubMed ID: 12465054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
    Mercuri NB; Scarponi M; Federici M; Bonci A; Siniscalchi A; Bernardi G
    Ann Neurol; 1998 May; 43(5):613-7. PubMed ID: 9585355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continued presence of intrastriatal but not intraventricular polymer-encapsulated PC12 cells is required for alleviation of behavioral deficits in Parkinsonian rodents.
    Emerich DF; Winn SR; Lindner MD
    Cell Transplant; 1996; 5(5):589-96. PubMed ID: 8889217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease.
    Andersson M; Hilbertson A; Cenci MA
    Neurobiol Dis; 1999 Dec; 6(6):461-74. PubMed ID: 10600402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P; Tremblay L; Féger J; Hirsch EC
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
    Glavan G; Zivin M
    Neuroscience; 2005; 135(2):545-54. PubMed ID: 16111820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E; Simola N; Borsini F; Schintu N; Frau L; Carminati P; Morelli M
    Eur J Pharmacol; 2007 Jul; 566(1-3):94-102. PubMed ID: 17445798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
    Srinivasan J; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):191-9. PubMed ID: 15084435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
    Ballion B; Frenois F; Zold CL; Chetrit J; Murer MG; Gonon F
    Neurobiol Dis; 2009 Sep; 35(3):376-84. PubMed ID: 19501163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expression of the calcium binding protein calretinin in the rat striatum: effects of dopamine depletion and L-DOPA treatment.
    Mura A; Feldon J; Mintz M
    Exp Neurol; 2000 Aug; 164(2):322-32. PubMed ID: 10915571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.